Literature DB >> 12529093

Testing strategies in the initial management of patients with community-acquired pneumonia.

Joshua P Metlay1, Michael J Fine.   

Abstract

The initial management of patients suspected of having community-acquired pneumonia is challenging because of the broad range of clinical presentations, potential life-threatening nature of the illness, and associated high costs of care. The initial testing strategies should accurately establish a diagnosis and prognosis in order to determine the optimal treatment strategy. The diagnosis is important in determining the need for antibiotic therapy, and the prognosis is important in determining the site of care. This paper reviews the test characteristics of the history, physical examination, and laboratory findings, individually and in combination, in diagnosing community-acquired pneumonia and predicting short-term risk for death from the infection. In addition, we consider the implications of these test characteristics from the perspective of decision thresholds. The history and physical examination cannot provide a high level of certainty in the diagnosis of community-acquired pneumonia, but the absence of vital sign abnormalities substantially reduces the probability of the infection. Chest radiography is considered the gold standard for pneumonia diagnosis; however, we do not know its sensitivity and specificity, and we have limited data on the costs of false-positive and false-negative results. In the absence of empirical evidence, the decision to order a chest radiograph needs to rely on expert opinion in seeking strategies to optimize the balance between harms and benefits. Once community-acquired pneumonia is diagnosed, a combination of history, physical examination, and laboratory items can help estimate the short-term risk for death and, along with the patient's psychosocial characteristics, determine the appropriate site of treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12529093     DOI: 10.7326/0003-4819-138-2-200301210-00012

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  50 in total

1.  Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care.

Authors:  Nick A Francis; Jochen W Cals; Christopher C Butler; Kerenza Hood; Theo Verheij; Paul Little; Herman Goossens; Samuel Coenen
Journal:  Prim Care Respir J       Date:  2012-03

Review 2.  Surgical management of non-mycobacterial fungal infections.

Authors:  Staci Beamer
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 3.  Pneumonia: update on diagnosis and management.

Authors:  Zara Hoare; Wei Shen Lim
Journal:  BMJ       Date:  2006-05-06

4.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 5.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 6.  South African guideline for the management of community-acquired pneumonia in adults.

Authors:  Tom H Boyles; Adrian Brink; Greg L Calligaro; Cheryl Cohen; Keertan Dheda; Gary Maartens; Guy A Richards; Richard van Zyl Smit; Clifford Smith; Sean Wasserman; Andrew C Whitelaw; Charles Feldman
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

7.  When the Script Doesn't Fit: An Exercise in Clinical Reasoning.

Authors:  Daniel J Wheeler; Thomas Cascino; Bradley A Sharpe; Denise M Connor
Journal:  J Gen Intern Med       Date:  2017-03-23       Impact factor: 5.128

8.  Fatty acid binding proteins as biomarkers of disease severity and response to treatment in severe pneumonia required admission to intensive care unit.

Authors:  Han-Chen Tsai; Shi-Chuan Chang
Journal:  Ann Transl Med       Date:  2016-10

9.  Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial.

Authors:  Jose Labarere; Roslyn A Stone; D Scott Obrosky; Donald M Yealy; Thomas P Meehan; Thomas E Auble; Jonathan M Fine; Louis G Graff; Michael J Fine
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

10.  Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.

Authors:  Dan Yamin; Ran D Balicer; Alison P Galvani
Journal:  Vaccine       Date:  2014-06-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.